Product Images Clopidogrel Bisulfate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Clopidogrel Bisulfate NDC 72162-2212 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

figure1 - clopidogrel fig

figure1 - clopidogrel fig

Figure 1 shows the exposure to Clopidogrel Active Metabolite following multiple doses of Clopidogrel 75 mg alone or with Proton Pump Inhibitors (PPIs). The table displays the effect of co-administered PPIs on the active metabolite AUC (area under the curve), along with the mean and 90% confidence interval. The PPIs mentioned include Deslansoprazole (60 mg), Lansoprszole (0 mg), Pantoprazole (80 mg), and Omeprazole (80 mg). It also indicates the change relative to Clopidogrel administered alone.*

figure3 - clopidogrel fig2

figure3 - clopidogrel fig2

This text appears to be a description of a clinical study evaluating the occurrence of cardiovascular death, myocardial infarction, and stroke in patients receiving different treatments. The treatments being compared are a placebo with aspirin and clopidogrel with aspirin. The cumulative event rate is presented, and the data suggests a statistically significant difference with a p-value of 0.00009. The study followed patients for a period of 12 months and mentions the use of other standard therapies alongside the tested treatments.*

figure3 - clopidogrel fig3

figure3 - clopidogrel fig3

figure4 - clopidogrel fig4

figure4 - clopidogrel fig4

This is a description of the results from the COMMIT Study, which evaluated the effects of a medication called Clopidogrel on death rates. The study compared the death rates of patients who received the placebo (1845 deaths, 8.1%) versus those who received Clopidogrel (1726 deaths, 7.5%). The results showed a 7% proportional risk reduction in death rates with Clopidogrel compared to the placebo, with a p-value of 0.03. The study followed patients for up to 28 days after randomization, and all treated patients received aspirin.*

figure5 - clopidogrel fig5

figure5 - clopidogrel fig5

This text appears to be providing information about a comparison between two treatments, Placebo and Clopidogrel. It mentions the number of events and the percentage of patients experiencing those events in each group. The text also mentions a 9% proportional risk and indicates a reduction in deaths with a p-value of 0.002. Additionally, there is mention of re-infarction or stroke occurring before the first discharge, and a timeline ranging from 7 to 28 days since randomization.*

figure6 - clopidogrel fig6

figure6 - clopidogrel fig6

figure7 - clopidogrel fig7

figure7 - clopidogrel fig7

figure8 - clopidogrel fig8

figure8 - clopidogrel fig8

structure - clopidogrel str

structure - clopidogrel str

Label - lbl721622212

Label - lbl721622212

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.